Recombinant Neuregulin 1 Does Not Activate Cardiomyocyte DNA Synthesis in Normal or Infarcted Adult Mice

Objectives Neuregulin 1 signaling plays an important role in cardiac trabecular development, and in sustaining functional integrity in adult hearts. Treatment with neuregulin 1 enhances adult cardiomyocyte differentiation, survival and/or function in vitro and in vivo. It has also been suggested that recombinant neuregulin 1β1 (NRG1β1) induces cardiomyocyte proliferation in normal and injured adult hearts. Here we further explore the impact of neuregulin 1 signaling on adult cardiomyocyte cell cycle activity. Methods and Results Adult mice were subjected to 9 consecutive daily injections of recombinant NRG1β1 or vehicle, and cardiomyocyte DNA synthesis was quantitated via bromodeoxyuridine (BrdU) incorporation, which was delivered using mini-osmotic pumps over the entire duration of NRG1β1 treatment. NRG1β1 treatment inhibited baseline rates of cardiomyocyte DNA synthesis in normal mice (cardiomyocyte labelling index: 0.019±0.005% vs. 0.003±0.001%, saline vs. NRG1β1, P<0.05). Acute NRG1β1 treatment did result in activation of Erk1/2 and cardiac myosin regulatory light chain (down-stream mediators of neuregulin signalling), as well as activation of DNA synthesis in non-cardiomyocytes, validating the biological activity of the recombinant protein. In other studies, mice were subjected to permanent coronary artery occlusion, and cardiomyocyte DNA synthesis was monitored via tritiated thymidine incorporation which was delivered as a single injection 7 days post-infarction. Daily NRG1β1 treatment had no impact on cardiomyocyte DNA synthesis in the infarcted myocardium (cardiomyocyte labelling index: 0.039±0.011% vs. 0.027±0.021%, saline vs. NRG1β1, P>0.05). Summary These data indicate that NRG1β1 treatment does not increase cardiomyocyte DNA synthesis (and consequently does not increase the rate of cardiomyocyte renewal) in normal or infarcted adult mouse hearts. Thus, any improvement in cardiac structure and function observed following neuregulin treatment of injured hearts likely occurs independently of overt myocardial regeneration.

[1]  S. Dimmeler,et al.  Breaking the silence: stimulating proliferation of adult cardiomyocytes. , 2009, Developmental cell.

[2]  Kevin Bersell,et al.  Neuregulin1/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury , 2009, Cell.

[3]  L. Field,et al.  Enhanced cardiomyocyte DNA synthesis during myocardial hypertrophy in mice expressing a modified TSC2 transgene. , 2000, Circulation research.

[4]  R. Graham,et al.  Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[5]  G. Koh,et al.  Formation of nascent intercalated disks between grafted fetal cardiomyocytes and host myocardium. , 1994, Science.

[6]  D. Opel,et al.  Neuregulins Promote Survival and Growth of Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[7]  Rüdiger Klein,et al.  Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.

[8]  L. Field,et al.  Expression of Mutant p193 and p53 Permits Cardiomyocyte Cell Cycle Reentry After Myocardial Infarction in Transgenic Mice , 2004, Circulation research.

[9]  J. Stull,et al.  The Effects of Neuregulin on Cardiac Myosin Light Chain Kinase Gene-Ablated Hearts , 2013, PloS one.

[10]  J. Ge,et al.  Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin. , 2010, Cardiovascular research.

[11]  L. Field,et al.  Cardiomyocyte Cell Cycle Activation Ameliorates Fibrosis in the Atrium , 2005, Circulation research.

[12]  Julian Taranda,et al.  Dilated cardiomyopathy in Erb-b4-deficient ventricular muscle. , 2005, American journal of physiology. Heart and circulatory physiology.

[13]  S. Houser,et al.  Repair of the Injured Adult Heart Involves New Myocytes Potentially Derived From Resident Cardiac Stem Cells , 2011, Circulation research.

[14]  S. Rohrbach,et al.  Neuregulin receptors erbB2 and erbB4 in failing human myocardium , 2005, Basic Research in Cardiology.

[15]  G. D. De Keulenaer,et al.  The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. , 2010, Circulation research.

[16]  P. Macdonald,et al.  Parenteral administration of recombinant human neuregulin‐1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses , 2011, European journal of heart failure.

[17]  D. Sawyer,et al.  Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. , 2003, Journal of molecular and cellular cardiology.

[18]  L. Field,et al.  Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. , 2000, Circulation research.

[19]  Richard T. Lee,et al.  Mammalian Heart Renewal by Preexisting Cardiomyocytes , 2012, Nature.

[20]  M. Soonpaa,et al.  Assessment of cardiomyocyte DNA synthesis in normal and injured adult mouse hearts. , 1997, The American journal of physiology.

[21]  V. Heinemann,et al.  Anticancer therapy induced cardiotoxicity: review of the literature , 2010, Anti-cancer drugs.

[22]  O. Frazier,et al.  Left ventricular unloading alters receptor tyrosine kinase expression in the failing human heart. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  D. Sawyer,et al.  Neuregulin in Cardiovascular Development and Disease , 2012, Circulation research.

[24]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Yibin Wang,et al.  p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. , 2005, Genes & development.

[26]  M. Soonpaa,et al.  Assessment of cardiomyocyte DNA synthesis during hypertrophy in adult mice. , 1994, The American journal of physiology.

[27]  D. Sawyer,et al.  NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. , 1999, The American journal of physiology.

[28]  E. Ballestar,et al.  Notch signaling is essential for ventricular chamber development. , 2007, Developmental cell.

[29]  D. Zipes,et al.  Stable fetal cardiomyocyte grafts in the hearts of dystrophic mice and dogs. , 1995, The Journal of clinical investigation.

[30]  Liuquan Cheng,et al.  A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. , 2010, Journal of the American College of Cardiology.

[31]  Douglas L Falls,et al.  Neuregulins: functions, forms, and signaling strategies. , 2003, Experimental cell research.

[32]  P. Sugden,et al.  ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium. , 2008, Journal of molecular and cellular cardiology.

[33]  C. Dickson,et al.  Congenital heart defects in Fgfr2-IIIb and Fgf10 mutant mice. , 2006, Cardiovascular research.

[34]  M. Rubart,et al.  Limitations of conventional approaches to identify myocyte nuclei in histologic sections of the heart. , 2010, American journal of physiology. Cell physiology.

[35]  G. Koh,et al.  Cyclin D1 overexpression promotes cardiomyocyte DNA synthesis and multinucleation in transgenic mice. , 1997, The Journal of clinical investigation.

[36]  Carmen Birchmeier,et al.  Multiple essential functions of neuregulin in development , 1995, Nature.

[37]  M. Soonpaa,et al.  Targeted Expression of Cyclin D2 Results in Cardiomyocyte DNA Synthesis and Infarct Regression in Transgenic Mice , 2004, Circulation research.

[38]  J. Loeb,et al.  Neuregulins: Versatile growth and differentiation factors in nervous system development and human disease , 2006, Brain Research Reviews.

[39]  Kuo-Fen Lee,et al.  Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.

[40]  F. Prósper,et al.  Controlled delivery of fibroblast growth factor-1 and neuregulin-1 from biodegradable microparticles promotes cardiac repair in a rat myocardial infarction model through activation of endogenous regeneration. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Maoyun Sun,et al.  Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. , 2009, American journal of physiology. Heart and circulatory physiology.

[42]  David A. Williams,et al.  Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts , 2004, Nature.

[43]  M. Rubart,et al.  Challenges measuring cardiomyocyte renewal. , 2013, Biochimica et biophysica acta.

[44]  D. Sawyer,et al.  Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. , 2006, Journal of molecular and cellular cardiology.

[45]  G. D. De Keulenaer,et al.  Role of Neuregulin-1/ErbB Signaling in Cardiovascular Physiology and Disease: Implications for Therapy of Heart Failure , 2007, Circulation.

[46]  B. Lorell,et al.  Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. , 1999, Circulation.

[47]  B. Creamer,et al.  The turnover and shedding of epithelial cells , 1961, Gut.

[48]  M. Soonpaa,et al.  Survey of studies examining mammalian cardiomyocyte DNA synthesis. , 1998, Circulation research.

[49]  T. Suter,et al.  Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1beta. , 2005, Journal of applied physiology.

[50]  T. Suter,et al.  Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. , 2006, Journal of molecular and cellular cardiology.

[51]  N. LeBrasseur,et al.  Cardiac Endothelial Cells Regulate Reactive Oxygen Species-induced Cardiomyocyte Apoptosis through Neuregulin-1β/erbB4 Signaling* , 2004, Journal of Biological Chemistry.